Reports Q4 revenue $16.8M, consensus $11.68M. "2022 was a successful year for Selecta. We delivered on key milestones across our pipeline and established strategic collaborations that have allowed us to drive forward our development programs," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta. "The Phase 3 DISSOLVE I and II clinical trials investigating SEL-212 in chronic refractory gout remains on track, and we expect to deliver topline data later this quarter. We look forward to the potential for SEL-212 to address the unmet needs of patients suffering from chronic refractory gout. In addition, we are currently enrolling patients in ReiMMAgine, our Phase 1/2 clinical trial of SEL-302 for the treatment of MMA. We intend to continue to leverage learnings from our clinical experience and growing safety database to propel our next-generation programs toward multiple IND filings and advance our wholly owned pipeline using ImmTOR in combination with a proprietary IL-2, which we believe has the potential to address the unmet need for precision immunotherapy for autoimmune diseases."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SELB:
- Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference
- Selecta Biosciences management to meet virtually with Cantor Fitzgerald
- Selecta Biosciences price target lowered to $9 from $10 at Canaccord
- Solid Biosciences appoints Tan as Chief Financial Officer
